Are you Dr. Lohr?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 36 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
Medical Oncology, Dfci, Smith 353
Boston, MA 02115Phone+1 617-632-3485
Summary
- Dr. Jens Lohr, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, Utah, and California. He is affiliated with Dana-Farber Cancer Institute and Brigham and Women's Hospital.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2012
- University of California (San Francisco)Residency, Internal Medicine, 2006 - 2008
- Ruprecht Karl University Faculty of MedicineClass of 1997
Certifications & Licensure
- CA State Medical License 2009 - 2026
- UT State Medical License 2024 - 2026
- MA State Medical License 2010 - 2025
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 738 citationsWidespread genetic heterogeneity in multiple myeloma: implications for targeted therapyJens G. Lohr, Petar Stojanov, Scott L. Carter, Peter Cruz-Gordillo, Michael S. Lawrence
Cancer Cell. 2014-01-13 - 3268 citationsMutational heterogeneity in cancer and the search for new cancer-associated genesMichael S. Lawrence, Petar Stojanov, Paz Polak, Gregory V. Kryukov, Kristian Cibulskis
Nature. 2013-07-11 - 518 citationsScalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumorsViktor A. Adalsteinsson, Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Daniel G. Stover
Nature Communications. 2017-11-06
Press Mentions
- American Thyroid Association Awards ThyCa Research Grant to Jens Lohr, MD, PhD, Dana Farber Cancer InstituteAugust 9th, 2017